Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Merck Sharp & Dohme LLC
Age
18–75
Sex
ALL
Healthy volunteers
Accepted
You may be eligible if
Is a continuous non-smoker or moderate smoker (of fewer than 20 cigarettes/day or equivalent)
Female participant is not pregnant or breastfeeding and is not woman of childbearing potential (WOCBP) or is a WOCBP using contraception or abstinent from heterosexual intercourse during the intervention period and for at least 14 days after the last dose of study intervention
(For hepatically impaired participants) Has a diagnosis of chronic (\>6 months), stable (no acute episodes within the previous 2 months due to deterioration in hepatic function) hepatic impairment
You may not be if
Has a history of clinically significant endocrine, gastrointestinal, cardiovascular, hematological, hepatic, immunological, renal, respiratory, genitourinary or major neurological abnormalities or diseases
Has a history of cancer; exceptions include (1) adequately treated non-melanomatous skin carcinoma or carcinoma in situ of the cervix, (2) other successfully treated malignancies
Has a history of significant multiple and/or severe allergies or has had significant intolerability to prescription or non-prescription drugs or food
Is positive for hepatitis B, hepatitis C or human immunodeficiency virus (HIV)
Has had major surgery or lost 1 unit of blood within 4 weeks prior to prestudy visit
Consumes greater than 3 glasses of alcoholic beverages per day
Consumes greater than 6 servings (1 serving is \~120 mg of caffeine) caffeinated beverages per day
(For hepatically impaired participants) Is taking medications to treat chronic medical conditions and has not been on a stable regimen for at least 1 month and/or is unable to withhold the use of the medications during study
Clareo Health | A Study to Investigate the Influence of Hepatic Impairment on Elpipodect (MK-8189) Treatment (MK-8189-012)
